Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Addressing the issue of resistance to TKIs in CML

Giuseppe Saglio • 28 Oct 2022
SOHO 2022
Chronic Myeloid Leukemia Leukemia Asciminib Ponatinib

Giuseppe Saglio, MD, University of Turin, Turin, Italy, describes known mechanisms of resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), highlighting the efficacy of ponatinib and asciminib in patients carrying the T315I mutation, and emphasizing the importance of better understanding the role of mutations in other genes than BCR-ABL1 in resistance to TKIs. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Giuseppe Saglio

2:26
An insight into the aims of the Eurasian Hematology-Oncology Group
Giuseppe Saglio • 25 Oct 2022
3:20
The current standard of care in CML and insights into the use of first- and second-generation TKIs
Giuseppe Saglio • 25 Oct 2022
3:35
TKI-related toxicities in CML & the importance of long-term monitoring
Giuseppe Saglio • 28 Sep 2022
2:36
Is it possible to achieve TFR with low-dose TKI therapy?
Giuseppe Saglio • 22 Oct 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals